Paper Details

  1. Home
  2. Paper Details

Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.

Author: , BernardinoJ I, CartonJ A, CurranA, DomingoP, FerrerE, GatellJ M, Gonzalez-CordonA, GutierrezF, MartinezE, MurillasJ, NegredoE, PeraireJ, PerezI, PichJ, PodzamczerD, PortillaJ, SantosI

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study examines the lipid effects and overall tolerability of ritonavir-boosted atazanavir and darunavir compared to ritonavir-boosted lopinavir in patients with HIV infection.
Paper Details　
Original Abstract of the Article :
Ritonavir-boosted atazanavir and darunavir are protease inhibitors that are recommended for initial treatment of HIV infection because each has shown better lipid effects and overall tolerability than ritonavir-boosted lopinavir. The extent to which lipid effects and overall tolerability differ betw...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/hiv.12121

データ提供：米国国立医学図書館（NLM）

Lipid Changes with Atazanavir/Ritonavir and Darunavir/Ritonavir

Atazanavir/ritonavir and darunavir/ritonavir are two protease inhibitors commonly used to treat HIV infection. This research explores the lipid profiles of patients taking these drugs, examining their effects on lipid levels, which play a crucial role in cardiovascular health. The researchers compared the lipid effects of atazanavir/ritonavir and darunavir/ritonavir, seeking to understand how these drugs impact metabolic health.

Navigating the Metabolic Landscape

The study found that both atazanavir/ritonavir and darunavir/ritonavir can cause significant lipid changes, although the specific effects varied between the two drug regimens. The study highlights the importance of monitoring lipid levels in patients taking these drugs and of managing any lipid abnormalities to mitigate the risk of cardiovascular disease. This research is like a desert expedition, exploring the complex landscape of metabolic effects of HIV medications.

Managing Lipid Effects in HIV Treatment

This research emphasizes the need for careful monitoring of lipid levels in patients taking atazanavir/ritonavir and darunavir/ritonavir. The study suggests that maintaining a healthy lifestyle, including a balanced diet and regular exercise, could help manage the lipid-related risks associated with these drugs. By understanding the metabolic impact of these medications, we can better navigate the desert of HIV treatment, ensuring the well-being of those living with the virus.

Dr. Camel's Conclusion

This research provides valuable insights into the metabolic effects of atazanavir/ritonavir and darunavir/ritonavir, two important protease inhibitors used to treat HIV infection. The study highlights the need for careful lipid monitoring and management in patients taking these drugs to mitigate the risk of cardiovascular disease. This research is a reminder that the journey through the desert of HIV treatment requires constant vigilance and careful attention to the complex interplay between medications and metabolic health.

Date :
  1. Date Completed 2015-02-04
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

24417772

DOI: Digital Object Identifier

10.1111/hiv.12121

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.